GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Total Equity

Satellos Bioscience (TSX:MSCL) Total Equity : C$34.50 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Total Equity?

Satellos Bioscience's total equity for the quarter that ended in Mar. 2024 was C$34.50 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Satellos Bioscience Total Equity Historical Data

The historical data trend for Satellos Bioscience's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Total Equity Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Equity
-0.18 10.48 3.37 40.67

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 49.19 46.36 40.67 34.50

Satellos Bioscience Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Satellos Bioscience's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=44.298-3.624
=40.67

Satellos Bioscience's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=38.255-3.754
=34.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satellos Bioscience Total Equity Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Total Equity
Comparable Companies
TSX:MBX TSXV:GSD TSX:ATE XCNQ:GLAB TSX:TH TSX:HBP TSXV:TTI XCNQ:ACOG TSXV:DMT TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MSCLF:USA 0IT:Germany
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines